Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

3O Association of ctDNA clearance with disease-free survival, safety, and quality of life from ctDNA-directed therapy: Findings from the ALTAIR study

ctDNA clearance at treatment completion was 17.2% with FTD/TPI vs 12.4% with placebo (P=0.367), a non-significant difference. Grade >=3 neutropenia occurred in 56.6% on FTD/TPI; 37.7% required dose reduction. Global health status declined at week 8 on FTD/TPI (P=0.028) but arms did not differ from week 24 onward. DFS results match the ASCO GI primary report (HR 0.79, P=0.107).

ESMO Gastrointestinal Cancers Congress 2025PubMed 42260101